Temat: intestinal microbiota - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Participation of gastrointestinal microbiome in the pathogenesis and symptoms of autism according to the theory of brain-intestinal axis interaction
Autorzy:: Stanisławek, Aneta Marta
Kozioł-Montewka, Maria
Powiązania:: https://bibliotekanauki.pl/articles/972492.pdf
Data publikacji:: 2017
Wydawca:: Instytut Medycyny Wsi
Tematy:: autism
autism spectrum disorder
intestinal microbiota
Opis:: Autism is a disorder involving a number of symptoms. It is included in the overall development disorders. The disease is characterized by spreading and progressive behavioural disorders, usually manifesting in early childhood and continuing also through adulthood. Epidemiological data emphasize the importance of the problem and the need to develop studies using modern molecular methods and next-generation sequencing techniques. and in the 1990’s – 10–20 per 10,000. Latest indexes show that child autism and Asperger syndrome affect 1 in 38 children. Recently, there has been published a detailed study on the intestinal microflora in children with autism, showing differences in the spectrum of microorganisms in sick and healthy children. One of the most striking discoveries is the fact that functions of the intestinal microflora and functions of the brain are connected. Therefore, it is possible that microbiome may influence a person’s behaviour and mental health. In the past, the impact of intestinal microflora on the development of autism was ignored, but today it is important. Digestive tract disorders occurring in children with autism can have various natures and locations. As of now, a single autism-specific digestive tract pathology cannot be claimed to exist. As in elimination diets, treatment should be conducted on an individual basis.
Źródło:: Journal of Pre-Clinical and Clinical Research; 2017, 11, 2; 153-156
1898-2395
Pojawia się w:: Journal of Pre-Clinical and Clinical Research
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: FECAL MICROBIOTA TRANSPLANTATION IN ADULTS AS A MODERN FORM OF PAST “COPROTHERAPY”: HOPE OR HYPE?
Autorzy:: Ksiądzyna, Dorota
Powiązania:: https://bibliotekanauki.pl/articles/895703.pdf
Data publikacji:: 2020-06-29
Wydawca:: Polskie Towarzystwo Farmaceutyczne
Tematy:: irritable bowel syndrome
dysbiosis
Clostridium difficile
fecal microbiota transplantation
intestinal microbiota
inflammatory bowel disorders
Opis:: The influence of intestinal microbiota on the human health and disease is of great importance. Fecal microbiota transplantation (FMT) defined as the transfer of the stool-derived microbiota of the distal gastrointestinal (GI) tract from a healthy donor to a patient with a disease attributable to intestinal dysbiosis is, in addition to the use of probiotics, prebiotics, synbiotics and eubiotics, one of the methods to restore eubiosis. Thorough medical history and physical examination followed by a set of blood and stool laboratory tests should be performed in a potential stool donor. Stool-derived microbiota may be administered through the upper and/or lower GI tract. FMT is believed to be a well-tolerated and, in general, safe procedure. The emergence of stool banks of frozen feces-derived material containing intestinal microbiota and the availability of convenient oral capsules with selected components of feces would definitely facilitate the use of this method in both research and the clinics. An inflammation caused by Clostridium difficile is the most often indication for FMT. Other conditions include inflammatory bowel disease, irritable bowel syndrome or the eradication of multi-drug resistant microorganisms. However, the list of potential indications rapidly increases. Further randomized double-blind studies in humans are needed to confirm a real benefit-risk ratio and clinical value of FMT, especially in extraintestinal disorders like obesity, diabetes mellitus, metabolic syndrome, fatty liver disease, hepatic encephalopathy, allergy, autism, depression or dementia.
Źródło:: Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 3; 391-401
0001-6837
2353-5288
Pojawia się w:: Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: In vitro anti-adherence effect of probiotic Lactobacillus strains on human enteropathogens
Autorzy:: Nowak, A.
Motyl, I.
Powiązania:: https://bibliotekanauki.pl/articles/410493.pdf
Data publikacji:: 2017
Wydawca:: Politechnika Łódzka. Wydawnictwo Politechniki Łódzkiej
Tematy:: adherence
intestinal microbiota
pathogens
inhibition
Caco-2 cells
przyczepność
mikrobiota jelitowa
patogeny
inhibicja
komórki Caco-2
Opis:: Probiotic bacteria possess great potential for producing antimicrobial substances that inhibit and control pathogenic bacteria in the human gastrointestinal tract. The aim of this study was to determine the anti-adherence properties of the probiotic Lactobacillus strains Lb. rhamnosus ŁOCK 0900, Lb. rhamnosus ŁOCK 0908, and Lb. casei ŁOCK 0919 (individually and in a 1:1:2 mixture) against the reference pathogens Clostridium difficile (ATCC 9689), Enterococcus faecalis (ATCC 29212), Listeria monocytogenes (ATCC 19115), and Staphylococcus aureus (ATCC 6538) using the Caco-2 human colon adenocarcinoma cell line. The mixture of probiotic strains inhibited the adherence of all pathogens, from 10.2% for E. faecalis ATCC 29212 to 97.2% for L. monocytogenes ATCC 19115. Of all the tested probiotic strains, Lb. casei ŁOCK 0919 reduced the adherence of S. aureus ATCC 6538 to the greatest extent (by 45.9%). These results suggest that adherence inhibition may involve competition for eukaryotic cell receptors and probiotic bacteria could protect the host cells from pathogen colonization and disease.
Źródło:: Biotechnology and Food Science; 2017, 81, 2; 103-112
2084-0136
2299-6818
Pojawia się w:: Biotechnology and Food Science
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 4.

Tytuł:: Przeszczep mikrobioty w leczeniu zakażenia Clostridium difficile
Microbiota transplant to treat Clostridium difficile infection
Autorzy:: Jamróz, Maciej
Powiązania:: https://bibliotekanauki.pl/articles/11236594.pdf
Data publikacji:: 2022
Wydawca:: Uczelnia Łazarskiego. Oficyna Wydawnicza
Tematy:: przeszczep mikrobioty kałowej
mikroflora jelitowa
zakażenie Clostridium difficile
fecal microbiota transplantation
intestinal microflora
Clostridium difficile infection
Opis:: Zakażenia bakterią Clostridium difficile są główną przyczyną biegunek poantybiotykowych i zakażeń wewnątrzszpitalnych. W ostatnich latach uległa zwiększeniu zapadalność na poantybiotykowe zakażenia wywołane przez Clostridium difficile, a przebieg choroby uległ pogorszeniu. Leczeniem z wyboru są nadal antybiotyki, mimo że przeszczep mikroflory jelitowej okazał się skuteczniejszy, osiągając wyniki ponad 90%, w badaniach randomizowanych. Podany jako leczenie pierwszego rzutu zmniejszył śmiertelność u chorych zakażonych Clostridium difficile wywołanymi hiperwirulentnymi szczepami bakterii (np. B1/NAP1/027). Obecnie, Europejskie Towarzystwo Mikrobiologii Klinicznej i Chorób Zakaźnych (ESCMID), zalicza transplantacje do arsenału terapeutycznego w postaciach nawracających. Lepsza znajomość mikroflory przewodu pokarmowego pozwoli rozszerzyć zakres wskazań do stosowania tej formy leczenia.
Clostridium difficile infections are the leading cause of antibioticinduced diarrhea and nosocomial infections. In recent years, the incidence of Clostridium difficile post-antibiotic infections has increased and the course of the disease has worsened. Antibiotics are still the treatment of choice, although intestinal microflora transplantation has been shown to be more effective, with over 90% in randomized trials. When given as first line therapy, it reduced mortality in patients with Clostridium difficile caused by hypervirulent strains of bacteria (e.g., B1/NAP1/027). Currently, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) includes transplantation in its therapeutic arsenal in relapsing forms. A better knowledge of the gastrointestinal microflora will extend the range of indications for this form of treatment.
Źródło:: Review of Medical Practice; 2022, XXVIII, 1-2; 85-88
2956-4441
2956-445X
Pojawia się w:: Review of Medical Practice
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "intestinal microbiota" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język